LU91852I2 - Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium - Google Patents

Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium

Info

Publication number: LU91852I2
Authority: LU; Luxembourg
Prior art keywords: tegafur; pharmaceutically acceptable; acceptable salt; gimeracil; oteracil
Prior art date: 1991-05-27

Application number

LU91852C

Other languages

English (en)

Original Assignee

Taiho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-05-27

Filing date

2011-08-03

Publication date

2011-10-03

2011-08-03 Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd

2011-10-03 Publication of LU91852I2 publication Critical patent/LU91852I2/fr

Links

RYYCJUAHISIHTL-UHFFFAOYSA-N 5-azaorotic acid Chemical compound OC(=O)C1=NC(=O)NC(=O)N1 RYYCJUAHISIHTL-UHFFFAOYSA-N 0.000 title abstract 3
229950000193 oteracil Drugs 0.000 title abstract 3
150000003839 salts Chemical class 0.000 title abstract 3
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 title abstract 3
229960001674 tegafur Drugs 0.000 title abstract 3
ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 title 1
229950009822 gimeracil Drugs 0.000 title 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
125000004093 cyano group Chemical group *C#N 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

LU91852C 1991-05-27 2011-08-03 Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium LU91852I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP12124791		1991-05-27
PCT/JP1992/000656 WO1992021345A1 (fr)	1991-05-27	1992-05-22	Composition, methode et trousse pour le traitement des tumeurs par stimulation de l'activite antitumorale

Publications (1)

Publication Number	Publication Date
LU91852I2 true LU91852I2 (fr)	2011-10-03

Family

ID=14806544

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU91852C LU91852I2 (fr)	1991-05-27	2011-08-03	Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium

Country Status (14)

Country	Link
US (1)	US5525603A (fr)
EP (1)	EP0543015B1 (fr)
JP (1)	JP2614164B2 (fr)
KR (1)	KR0148589B1 (fr)
AT (1)	ATE173165T1 (fr)
AU (1)	AU654555B2 (fr)
CA (1)	CA2087540C (fr)
DE (2)	DE69227571T2 (fr)
DK (1)	DK0543015T3 (fr)
ES (1)	ES2124257T4 (fr)
HU (1)	HU211987A9 (fr)
LU (1)	LU91852I2 (fr)
TW (1)	TW209833B (fr)
WO (1)	WO1992021345A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5719132A (en) *	1996-06-27	1998-02-17	Bristol-Myers Squibb Company	Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
NZ330360A (en) *	1997-06-02	1999-03-29	Hoffmann La Roche	5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
JPH11116564A (ja) *	1997-10-09	1999-04-27	Otsuka Chem Co Ltd	クロモン誘導体
US6005098A (en) *	1998-02-06	1999-12-21	Hoffmann-La Roche Inc.	5'deoxycytidine derivatives
US6538001B1 (en) *	1998-10-12	2003-03-25	Nikolai Borisovich Leonidov	Crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl) uracil and complex compounds based thereon, producing antineoplastic effect
JP2002255828A (ja) *	2001-02-28	2002-09-11	Ajinomoto Co Inc	抗腫瘍剤
RU2346686C2 (ru) *	2002-01-14	2009-02-20	Новартис Аг	Комбинации, включающие эпотилоны и антиметаболиты
CN101357134A (zh) *	2003-03-14	2009-02-04	大鹏药品工业株式会社	抗肿瘤效果增强剂和抗肿瘤剂
SI1750703T1 (sl) *	2004-04-29	2012-02-29	Taiho Pharmaceutical Co Ltd	Postopek za zmanjšanje gastrointestinalne toksičnosti zaradi dajanja tegafurja
KR100844477B1 (ko)	2004-06-09	2008-07-07	다이호야쿠힌고교 가부시키가이샤	항종양 효과 증강제, 항종양제 및 암 치료 방법
CN101912399B (zh) *	2005-04-01	2012-05-23	大鹏药品工业株式会社	放射线治疗增强剂
JP4994618B2 (ja) *	2005-08-11	2012-08-08	学校法人北里研究所	Ｔｓ−１／カンプトテシン類による化学放射線療法
US8198264B2 (en) *	2006-04-28	2012-06-12	National Cancer Center	Method for treating head and neck cancer
CN101921227B (zh) *	2007-04-03	2012-09-05	南京工业大学	5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
TWI468188B (zh)	2008-01-30	2015-01-11	Univ Tokushima	Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
AU2008356312B2 (en)	2008-05-12	2015-04-09	Shizuoka Prefecture	Antitumor agent, kit, and method for treating cancer
WO2010104035A1 (fr)	2009-03-12	2010-09-16	学校法人近畿大学	Procédé permettant de prédire l'efficacité thérapeutique de la chimiothérapie sur le cancer du poumon non à petites cellules
PL2415870T3 (pl)	2009-03-31	2017-01-31	Delta-Fly Pharma, Inc.	Cząsteczka RNAi dla syntazy tymidylanowej i jej zastosowanie
US8992947B2 (en)	2009-04-22	2015-03-31	Taiho Pharmaceutical Co., Ltd.	Method for predicting therapeutic effect of chemotherapy on renal cell cancer
AU2010248710A1 (en)	2009-05-12	2011-12-01	Taiho Pharmaceutical Co., Ltd.	Anti-tumor agent containing tegafur-gimeracil-oteracil potassium combination drug and oxaliplatin
WO2011052554A1 (fr)	2009-10-27	2011-05-05	Ｄｅｌｔａ－ＦｌｙＰｈａｒｍａ株式会社	Nouveau dérivé de 5-fluorouracile
CN102309491B (zh) *	2010-07-02	2015-06-10	天津金耀集团有限公司	一种替加氟、吉美斯特复方注射液
JPWO2012105486A1 (ja)	2011-01-31	2014-07-03	大鵬薬品工業株式会社	１日１回隔日投与を特徴とするテガフール含有組成物
EP2711704B1 (fr)	2011-05-16	2017-06-28	Taiho Pharmaceutical Co., Ltd.	Méthode de sélection, pour un patient souffrant d'un cancer de l'estomac, d'une chimiothérapie associant tégafur, giméracil et otéracil (oxonate de potassium), et inhibiteur de l'egfr
AU2012259803B2 (en) *	2011-05-25	2016-03-17	Taiho Pharmaceutical Co., Ltd.	Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
CN103159673B (zh) *	2011-12-12	2015-02-04	山东新时代药业有限公司	一种制备吉美嘧啶的精制方法
US20150110864A1 (en)	2012-03-16	2015-04-23	Taiho Pharmaceutical Co., Ltd.	Novel antitumor agent comprising combination of three agents
TW201400810A (zh) *	2012-06-01	2014-01-01	大鵬藥品工業股份有限公司	對胃癌患者選擇化學療法之方法
CN114436822B (zh) *	2022-01-12	2024-04-16	厦门稀土材料研究所	一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS55111420A (en) *	1979-02-20	1980-08-28	Ono Pharmaceut Co Ltd	Antitumorigenic agent
JPS562913A (en) *	1979-06-21	1981-01-13	Ono Pharmaceut Co Ltd	Antitumor agent
JPS5646867A (en) *	1979-09-25	1981-04-28	Ono Pharmaceut Co Ltd	Pyridone derivative, its preparation and antineoplasmic agent
DK175432B1 (da) *	1984-10-30	2004-10-18	Otsuka Pharma Co Ltd	Middel til forögelse af anticancervirkningen af anticancerforbindelser
JPS62155215A (ja) *	1984-11-30	1987-07-10	Otsuka Pharmaceut Co Ltd	抗腫瘍活性増強剤
US5116600A (en) *	1989-01-05	1992-05-26	Otsuka Pharmaceutical Co., Ltd.	Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds
JPH0578249A (ja) *	1991-09-20	1993-03-30	Taiho Yakuhin Kogyo Kk	５−フルオロウラシル類により起こる嘔気・嘔吐の防止及び治療剤

1992
- 1992-05-22 KR KR1019930700243A patent/KR0148589B1/ko not_active Expired - Lifetime
- 1992-05-22 CA CA002087540A patent/CA2087540C/fr not_active Expired - Lifetime
- 1992-05-22 ES ES92910345T patent/ES2124257T4/es not_active Expired - Lifetime
- 1992-05-22 DE DE69227571T patent/DE69227571T2/de not_active Expired - Lifetime
- 1992-05-22 WO PCT/JP1992/000656 patent/WO1992021345A1/fr not_active Ceased
- 1992-05-22 AT AT92910345T patent/ATE173165T1/de active
- 1992-05-22 EP EP92910345A patent/EP0543015B1/fr not_active Expired - Lifetime
- 1992-05-22 DK DK92910345T patent/DK0543015T3/da active
- 1992-05-22 JP JP4510539A patent/JP2614164B2/ja not_active Expired - Lifetime
- 1992-05-22 DE DE201112100040 patent/DE122011100040I2/de active Active
- 1992-05-22 AU AU17912/92A patent/AU654555B2/en not_active Expired
- 1992-05-23 TW TW081104041A patent/TW209833B/zh not_active IP Right Cessation
1995
- 1995-03-30 US US08/414,127 patent/US5525603A/en not_active Expired - Lifetime
- 1995-06-30 HU HU95P/P00727P patent/HU211987A9/hu active Protection Beyond IP Right Term
2011
- 2011-08-03 LU LU91852C patent/LU91852I2/fr unknown

Also Published As

Publication number	Publication date
KR0148589B1 (ko)	1998-11-02
WO1992021345A1 (fr)	1992-12-10
TW209833B (fr)	1993-07-21
EP0543015A4 (en)	1994-06-01
EP0543015A1 (fr)	1993-05-26
CA2087540A1 (fr)	1992-11-28
US5525603A (en)	1996-06-11
JP2614164B2 (ja)	1997-05-28
CA2087540C (fr)	1999-01-19
DE122011100040I1 (de)	2011-11-24
AU654555B2 (en)	1994-11-10
DE69227571D1 (de)	1998-12-17
EP0543015B1 (fr)	1998-11-11
AU1791292A (en)	1993-01-08
ES2124257T3 (es)	1999-02-01
ATE173165T1 (de)	1998-11-15
ES2124257T4 (es)	2012-03-23
DE69227571T2 (de)	1999-04-29
DK0543015T3 (da)	1999-07-26
DE122011100040I2 (de)	2012-08-09
HU211987A9 (en)	1996-01-29

Publication	Publication Date	Title
EP0543015A4 (en)	1994-06-01	Composition, method and kit for potentiating antitumor activity and for curing tumor
NO2006018I1 (no)	2006-12-27	Entekavir:(2-amino-1,9-dihydro-9Ä(1S,3R,4S)-4hydroksy-3-(hydroksymetyl)-2-metylencyklopentylÜ-6H-purin-6-on og hydrater derav, saerlig monohydrat
CA2209598A1 (fr)	1997-05-22	Composes d'arylpurine et d'heteroarylpurine
PL377285A1 (pl)	2006-01-23	Podstawione pochodne pirolo-pirazolowe jako inhibitory kinazy
PL293316A1 (en)	1993-08-23	Method of obtaining quinozolinone derivatives
FI900085A0 (fi)	1990-01-08	Menetelmä terapeuttisesti käyttökelpoisten N-(pyrimidin- ja kondensoitu pyrimidin-4-oni)etyyli-piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
WO2004052893A3 (fr)	2004-08-12	Derives dihydropyrano indole-3,4-dione substitues servant d'inhibiteurs d'un inhibiteur 1 d'activateur du plasminogene (pai-1)
DK0386675T3 (da)	1996-06-24	Xanthinderivater
DE69717827D1 (de)	2003-01-23	Benzofuran-4-carboxamide
DK0650961T3 (da)	1997-09-15	Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
EA200100994A1 (ru)	2002-06-27	1-АМИНОТРИАЗОЛО[4,3-а]ХИНАЗОЛИН-5-ОНЫ И/ИЛИ -5-ТИОНЫ, ИНГИБИРУЮЩИЕ ФОСФОДИЭСТЕРАЗУ-IV
EP0322738A3 (fr)	1991-05-08	Dérivés de la benzylidène pour l'inhibition des processus de prolifération dans les cellules des mammifères
AU2097492A (en)	1993-02-25	Composition and method for treating cancer
DE69414019D1 (de)	1998-11-26	Bicyclische Stichstoff enthaltende Derivate als Prolyl-Endopeptidase Inhibitoren
ATE191317T1 (de)	2000-04-15	Verwendung von beta-aminopropionsäure-derivaten als fungizide
AU2101592A (en)	1993-02-18	Piperidine derivatives
EP0202062A3 (fr)	1987-08-19	Dérivés de quinuclidine
ES2087247T3 (es)	1996-07-16	Inhibidor de aldosa reductasa.
DE60036558D1 (de)	2007-11-08	Phthalazinon-derivate als pde 4 hemmer
HUT75649A (en)	1997-05-28	Optically active imidazolidinone derivative and pharmaceutical compositions containing them
CA2058398A1 (fr)	1992-06-28	Derives d'acide 1,4-benzothiazine-2-acetique; methode de preparation
DE69529807D1 (de)	2003-04-10	Neue Parabansäure-Derivate als Aldose-Reduktase Inhibitoren
JPS574977A (en)	1982-01-11	2-guanidinothiazole derivative
AU7935887A (en)	1988-04-14	Therapeutic agent for the treatment of peptic ulcer disease
EP1028118A4 (fr)	2003-01-22	Procede de production de composes de 3 cephems